2025年全球肝炎峰会(GHS)-第19届国际病毒性肝炎与肝病研讨会

◆ 会议时间：2025年3月18-21日
◆ 会议地点：美国洛杉矶

◆ 会议简介：

2025年全球肝炎峰会(GHS2025)-第19届国际病毒性肝炎与肝病研讨会将于2025年3月18-21日在美国洛杉矶举行。作为ISVHLD的传统，全球肝炎峰会将汇集来自世界各地的顶级临床医生和研究人员。为期四天密集而又充满活力的科学会议，将为当前肝炎发展各方面的所有参与者提供了众多学习机会。ISVHLD将邀请100多位国际知名的演讲者，主持有关病毒性肝炎和肝病基础、临床和公共卫生科学领域的全体会议和平行科学会议，他们不仅在诊断、治疗等方面有丰富的知识和经验，而且在病毒性肝炎、HCC、NASH等肝病的治疗方面也有着丰富的经验；世界领先的优秀科学计划委员会将制定最高质量的科学教育计划，提供突破性的摘要、科学海报和电子海报、行业研讨会、招待会、社交活动、展览等等，预计将有1500余名来自世界各地的一流临床医生和研究人员参会。未经许可禁止复制摘录本站任何内容-国际医学会议网(lingyuint.com)

Global Hepatitis Summit (GHS 2025)
19th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)

Date: March 18-21, 2025
Venue: Los Angele, USA

摘要征文投稿：

ABSTRACT SUBMISSION GUIDELINES

Abstracts must be submitted electronically using the official online submission form

Abstracts must identify the presenting author along with email address

Please use standard abbreviations. Place special or unusual abbreviations in parenthesis after the full word when it appears for the first time

Errors, misspellings, and incorrect abbreviations will not be corrected

Abstracts will be presented in capital letter case

An individual may submit more than one (1) abstract. One official online submission is required for each abstract

Edits to submitted abstracts may be made up to the submission deadline. Instructions for making edits can be found on the submission site

Abstracts must be submitted by October 9, 2024 to be considered for presentation.

ABSTRACT TYPES

During the online abstract submission, authors will be requested to select their preferred method of presentation: Oral or Poster Presentation or Poster only Presentation.

Presentation method preferences will be considered during the review process.

SESSION THEMES (TOPICS)

Themes (topics) for each of the sessions are listed below. Please submit your abstract within the Basic Science, Clinical or Public Health streams under one of the following subtopics:

Basic-translational science categories

1. HCV/flavivirus virology
2. HCV/flavivirus immunology
3. HBV/HDV virology
4. HBV/HDV immunology
5. Preclinical therapeutics HBV/HDV
6. Hepatocellular carcinoma
7. Other viruses (including HEV)
8. Liver inflammation and fibrogenesis
9. Liver pathogen detection and discovery

Clinical science categories

10. HCV screening, clinical care delivery and outcomes
11. HBV screening, clinical care delivery and outcomes
12. Approved HBV treatments
13. New and promising HBV therapies (Phase 2 and beyond) and diagnostics
14. Approved and promising new HDV therapies and diagnostics
15. Viral hepatitis coinfections and morbidities: HIV, MASLD/MASH
16. Hepatocellular carcinoma clinical
17. Hepatocellular carcinoma treatment
18. Biomarkers for liver diseases
19. Other viruses, clinical and treatment

Public Health categories

20. Prevention of new infections, including vaccination and injection safety
21. Epidemiology of HCV
22. Epidemiology of HBV/HDV
23. Epidemiology of hepatocellular carcinoma
24. HBV elimination: achievements and challenges
25. HCV elimination: achievements and challenges
26. Simplified community and clinic- based approaches to viral hepatitis care cascade
27. Strategies for equitable service delivery to overcome disparities in viral hepatitis

The abstract review committee reserves the right to reassign submitted abstracts to a different session.

ABSTRACT FORMATTING GUIDELINES

Please adhere to the following formatting guidelines when submitting your abstracts for GHS 2025. Abstracts that are not correctly formatted will not be reviewed.

The abstract title should not exceed 300 characters

The abstracts should not exceed 3,000 characters

Each abstract is allowed to include a maximum of three (3) caption (figure or table) but this is not a requirement. Minimize the use of charts and graphics as this detail is not used to evaluate the merit of your abstract

There is no restriction on your abstract structure, but we recommended the following:
- Title
- Background
- Purpose
- Method(s)
- Result(s)
- onclusion(s)

NOTIFICATION OF ACCEPTANCE

Presenting authors will be notified of their acceptance status in early November 2024. Presenting authors must inform any co-author(s) of acceptance. The organizing committee reserves the right to accept or decline any submissions and to select the presentation format (oral or poster).

DISCLOSURE OF CONFLICTS OF INTEREST

The presenting authors of abstracts selected for oral presentation will be required to complete and submit a Disclosure of Conflicts of Interest form after they are invited to present. Disclosures are due on or before the RSVP deadline.

DISCLAIMER REGARDING THE SUBMISSION OF ABSTRACTS

The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events.

Dear Friends and Colleagues,

It is with great pleasure that we invite you to join us in Los Angeles, USA March 18 – 21, 2025 for the 19th Global Hepatitis Summit (GHS 2025), a 50-year legacy of the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).

The GHS 2025 faculty has been carefully selected to achieve the global diversity and gender balance that is reflective of our scientific community today. 2025 will feature a unique interdisciplinary Summit designed to share the latest developments in all aspects of liver diseases, including viral hepatitis, non-alcoholic fatty liver disease, hepatocellular carcinoma and so on. It will encompass the continuum of research from basic science to clinical research and public health applications.

GHS 2025 will be as much a networking event as a cutting-edge research conference, featuring dedicated tracks for health practitioners and inspiring workshops for those working in the liver and hepatitis space, where renown speakers will highlight the most exciting recent results in the field and provide perspectives for research and patient management.

Multidisciplinary focus for all areas of interest will include basic science, translational research, development of novel diagnostic tools and therapies, and approaches to control and eliminate liver diseases as public health threats.

It will be our pleasure to welcome you to Los Angeles for this historic scientific meeting.

With kind regards,

Norah Terrault
Co-Chair